InsiderTradesSIGMA

InsidersTradesSigma

← Executives ★ Sign in to follow

MC

M. Colpan

Director

BoardM

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Insider track record

Board Director

Disclosed buys

0

Disclosed sells

0

T+90 hit rate

45%

T+90 mean return

+2.0%

Across 64 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Discover the complete record of transactions filed by M. Colpan, Director. Officer active across 1 company, notably Qiagen N.V.. Aggregated, 120 disclosures have been recorded. History available since 1 November 2006. The latest transaction was filed on 19 August 2024 (Sale). Regulator: AFM. The full history is accessible without signup.

Declarations120 total

●

Director or Supervisory BoardExecutives28 Feb 2026Qiagen N.V.

-9,156 sharesRestricted share awardAFM:189033

●

Director or Supervisory BoardExecutives27 Feb 2026Qiagen N.V.

4,618 sharesRestricted share awardAFM:189004

Ideal exit: 24 Nov 2026 (T+270)

●

Director or Supervisory BoardExecutives26 Feb 2026Qiagen N.V.

-4,490 sharesRestricted share awardAFM:188862

●

Director or Supervisory BoardExecutives7 Jan 2026Qiagen N.V.

-8,804 sharesGewoon aandeelAFM:185870

●

Director or Supervisory BoardExecutives28 Feb 2025Qiagen N.V.

-2,458 sharesRestricted share awardAFM:170825

●

Director or Supervisory BoardExecutives28 Jan 2025Qiagen N.V.

-4,910 sharesGewoon aandeelAFM:169256

●

Director or Supervisory BoardExecutives19 Aug 2024Qiagen N.V.

€1M18AFM ↗

-27,616 shares@ €42.19330.6% of flowGewoon aandeelAFM:162495

●

Director or Supervisory BoardExecutives16 Aug 2024Qiagen N.V.

€4M18AFM ↗

-98,544 shares@ €42.26312.1% of flowGewoon aandeelAFM:162431

●

Director or Supervisory BoardExecutives15 Aug 2024Qiagen N.V.

€2M18AFM ↗

-50,973 shares@ €42.07471.1% of flowGewoon aandeelAFM:162353

●

Director or Supervisory BoardExecutives14 Aug 2024Qiagen N.V.

€3M18AFM ↗

-61,367 shares@ €41.7941.3% of flowGewoon aandeelAFM:162320

●

Director or Supervisory BoardExecutives29 Feb 2024Qiagen N.V.

7,056 sharesRestricted share awardAFM:154858

Ideal exit: 25 Nov 2024 (T+270)

●

Director or Supervisory BoardExecutives28 Feb 2024Qiagen N.V.

-5,599 sharesRestricted share awardAFM:154972

●

Director or Supervisory BoardExecutives26 Feb 2024Qiagen N.V.

-2,992 sharesRestricted share awardAFM:154855

●

Director or Supervisory BoardExecutives29 Jan 2024Qiagen N.V.

-12,710 sharesGewoon aandeelAFM:153268

●

Director or Supervisory BoardExecutives28 Feb 2023Qiagen N.V.

-1,773 sharesRestricted share awardAFM:137660

●

Director or Supervisory BoardExecutives31 Oct 2022Qiagen N.V.

-457 sharesRestricted share awardAFM:132941

●

Director or Supervisory BoardExecutives1 Mar 2022Qiagen N.V.

-544 sharesRestricted share awardAFM:120923

●

Director or Supervisory BoardExecutives28 Feb 2022Qiagen N.V.

-3,192 sharesRestricted share awardAFM:120855

●

Director or Supervisory BoardExecutives1 Mar 2021Qiagen N.V.

-6,446 sharesRestricted share awardAFM:106800

●

Director or Supervisory BoardExecutives28 Feb 2021Qiagen N.V.

-4,414 sharesRestricted share awardAFM:106758

●

Director or Supervisory BoardExecutives26 Feb 2021Qiagen N.V.

7,482 sharesRestricted share awardAFM:106757

Ideal exit: 23 Nov 2021 (T+270)

●

Director or Supervisory BoardExecutives17 Feb 2021Qiagen N.V.

€12M19AFM ↗

-274,784 shares@ €45.44846.3% of flowGewoon aandeelAFM:106340

●

Director or Supervisory BoardExecutives16 Feb 2021Qiagen N.V.

€23M19AFM ↗

-495,586 shares@ €45.748211.5% of flowGewoon aandeelAFM:106282

●

Director or Supervisory BoardExecutives17 Dec 2020Qiagen N.V.

€45M20AFM ↗

-1,080,308 shares@ €41.895123.0% of flowGewoon aandeelAFM:103242

●

Director or Supervisory BoardExecutives16 Dec 2020Qiagen N.V.

€19M19AFM ↗

-462,264 shares@ €42.17859.9% of flowGewoon aandeelAFM:103198

25 of 120 declarations

About M. Colpan

M. Colpan is a Director or Supervisory Board member at Qiagen N.V. He contributes to the governance of the company and strategic decision-making. With expertise in the biopharmaceutical sector, he plays a key role in guiding projects and growth initiatives.